The wizards of odds: cost-effectiveness, Barrett's screening, and surveillance guidelines.
David G
DG
Perdue
Joseph
J
Murray
Kenneth K
KK
Wang
D000230:Adenocarcinoma / Q000175:diagnosis* / Q000517:prevention & control; D001471:Barrett Esophagus / Q000150:complications / Q000175:diagnosis*; D003362:Cost-Benefit Analysis; D004938:Esophageal Neoplasms / Q000175:diagnosis* / Q000517:prevention & control; D004945:Esophagoscopy / Q000191:economics; D005764:Gastroesophageal Reflux / Q000150:complications; D006801:Humans; D008403:Mass Screening / Q000191:economics*; D011159:Population Surveillance; D011230:Precancerous Conditions / Q000175:diagnosis*; D019057:Quality-Adjusted Life Years; D014481:United States / Q000453:epidemiology